SOVALDI 400mg Price in UAE

Overview

Welcome to Dwaey, specifically on SOVALDI 400mg page.
This medicine contains an important and useful components, as it consists of
Sofosbuviris available in the market in concentration

Name

Sofosbuvir

Precaution

Pregnancy: Ribavirin may cause birth defects and fetal death and animal studies have shown interferons have abortifacient effects; avoid pregnancy in female patients and female partners of male patients. Patients must have a negative pregnancy test prior to initiating therapy, use at least 2 effective methods of contraception and have monthly pregnancy tests. Lactation: Unknown if distributed in human breast milk; take into account the importance of therapy to the mother when administered combination with ribavirin and/or peg-interferon alfa; because of the potential for adverse reaction, breastfeeding is not recommended

Indication

Chronic Hepatitis C, Patients with hepatocellular carcinoma awaiting liver transplantation

Contra indication

When Sofosbivur is used in combination with Ribavirin or Peginterferon alfa/Ribavirin, the contraindications applicable to those agents are applicable to combination therapies. Sofosbuvir combination treatment with Ribavirin or Peginterferon alfa/Ribavirin is contraindicated in women who are pregnant or may become pregnant and men whose female partners are pregnant, because of the risks for birth defects and fetal death associated with Ribavirin.

Side Effect

>10% Sofosbuvir plus ribavarin (12 weeks) Fatigue (38%),Headache (24%),Nausea (22%),Insomnia (15%),Pruritus (11%),Sofosbuvir plus ribavarin (24 weeks),Fatigue (30%),Headache (30%),Nausea (13%),Insomnia (16%),Pruritus (27%),Asthenia (21%),Diarrhea (12%) Sofosbuvir plus ribavarin plus peg-interferon (12 weeks) Fatigue (59%),Headache (36%),Nausea (34%),Insomnia (25%),Pruritus (17%),Anemia (21%),Rash (18%),Decreased appetite (18%),Chills (17%),Influenza-like illness (16%),Pyrexia (18%),Diarrhea (12%),Neutropenia (17%),Myalgia (14%),Irritability (13%) Sofosbuvir plus ribavarin plus peg-interferon (24 weeks) Fatigue (55%),Headache (44%),Nausea (29%),Insomnia (29%),Pruritus (17%),Anemia (12%),Rash (18%),Decreased appetite (18%),Chills (18%),Influenza-like illness (18%),Pyrexia (14%),Diarrhea (17%),Neutropenia (12%),Myalgia (16%),Irritability (16%) 1-10% Sofosbuvir plus ribavarin (12 weeks) Anemia (10%),Asthenia (6%),Rash (8%),Decreased appetite (6%),Chills (2%),Influenza-like sickness (3%),Pyrexia (4%),Diarrhea (9%),Myalgia (6%),Irritability (10%) Sofosbuvir plus ribavarin (24 weeks) Anemia (6%),Rash (9%),Decreased appetite (6%),Chills (2%),Influenza-like sickness (6%),Pyrexia (4%),Myalgia (9%),Irritability (10%) <1% Neutropenia,Pancytopenia,Severe depression (particularly in patients with pre-existing psychiatric illness)

Pregnancy Category ID

2

Mode of Action

Nucleotide prodrug that undergoes metabolism to the active uridine analog triphosphate, an inhibitor of HCV NS5B RNA-dependent polymerase; its inhibition in turn suppresses viral replication .

Interaction

Reduced therapeutic effect w/ drugs that are potent P-gp inducers in the intestine (eg rifampicin, St. John's wort, carbamazepine & phenytoin), modafinil, phenobarb/oxcarbazepine, rifabutin/rifapentine. P-gp &/or BCRP inhibitors. May result in serious symptomatic bradycardia when co-administered w/ amiodarone in combination w/ another direct acting antiviral.